PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
نویسندگان
چکیده
Introduction Canakinumab (CAN), a selective, fully human, antiinterleukin-1b monoclonal antibody, has been shown to be efficacious in SJIA patients (pts) in 2 phase 3 trials: Trial 1 (4-wk, randomized placebo [PBO]-controlled) and Trial 2 (open-label CAN treatment [Part 1] followed by a randomized PBO-controlled withdrawal phase [Part 2]). In Trial 1, statistically significantly more CAN than PBO group pts achieved an adapted pediatric ACR 30 response and in Trial 2, CAN allowed successful reduction/ discontinuation of steroids and significantly reduced risk of flare. Safety profile of CAN was in line with expectations for a biologic agent in active SJIA. The persistent disabling features of SJIA and chronic pain can have a negative impact on health-related quality of life (hrqol). These outcomes were evaluated in the CAN phase 3 program.
منابع مشابه
PReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
Introduction Systemic juvenile idiopathic arthritis (SJIA) is the most common subtype of JIA in Thailand, which represents approximately 33 percents of all JIA patients. The disease course of SJIA and outcome of treatment were varied, depending on multi-factors. In the previous studies, persistent systemic features, younger age at onset, and arthritis of hip are predictors of poor functional ou...
متن کاملPReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy N Nirmala, N Wulffraat, H Brunner, P Quartier, R Brik, L Mccann, H Ozdogan, L Rutkowska-Sak, R Schneider, V Gerloni, L Harel, M Terreri, K Houghton, R Joos, D Kingsbury, J Lopez-Benitez, S Radominski, A Brachat, S Bek, M Schumacher, M Valentin...
متن کاملAssessment of Health Related Quality of Life (HRQL) in Egyptian Children with Rheumatic Diseases; Its Relation to Disease Activity and Functional Disability
Background Many pediatric rheumatic diseases persist into adulthood, with negative squeal from the disease or its treatment. We aimed to assess health related quality of life in a group of children with rheumatic diseases and its relation to disease activity and functional disability. Materials and Methods Fifty one patients were divided into three groups: Group 1 includes 27 patients diagnose...
متن کاملPReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
Methods Data from the 3 trials done as part of the phase III program were pooled for this analysis. Pts aged 2-19 yrs with active SJIA were enrolled and received subcutaneous CAN 4 mg/kg or placebo. The post-hoc analysis presented here focuses on SJIA response to CAN therapy in the initial treatment period of a total of 178 CAN-naïve pts. Methodological factors precluded a comparator group, so ...
متن کاملEfficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
OBJECTIVES To describe the efficacy, safety, and exposure-response relationship of canakinumab in a subgroup of patients with systemic juvenile idiopathic arthritis (SJIA) aged ≥16 years, representative of adult-onset Still's disease (AOSD) patients, and to compare this subgroup with those of children and young adolescents with SJIA by pooling clinical data collected during the development prog...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2013